author-photo

Zanete Zvirbule

University of Southern California

17

Papers

618

Citations

Citation Trend

Filter By

Papers (17) Sort By

JournalConferenceOthers

Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

2021 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (0)
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.

2017 International Journal of Gynecological Cancer
Show All
- Source
- Cite
- Save
Citations (40)
Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (72)
Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (35)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号